The US FDA Approves Citius Pharmaceuticals’ Lymphir to Treat R/R Cutaneous T-Cell Lymphoma (CTCL)
Shots:
- The US FDA has granted approval to Lymphir for treating chronic r/r CTCL in patients treated with at least one prior systemic therapy, with its introduction anticipated within the next 5mos.
- The approval was based on P-III (Study 302) trial assessing the safety & efficacy of Lymphir (9mcg/kg, IV) among patients (n=69) with r/r CTCL (stage I to IV)
- The study showed an ORR of 36.2%, CR in 8.7%, median time to response of 1.41mos. in ~70% post 1–2 cycles of treatment and DoR of at least 6mos. in 52%. 84.4% of them showed reduced skin tumor burden, with 12.5% achieving complete skin clearance. Pruritus improved in 31.7% of patients without any cumulative toxicity
Ref: Citius Pharmaceuticals | Image: Citius Pharmaceuticals
Related News:- Laekna’s LAE002(Afuresertib) + LAE001 Receives FDA Approval for P-III Trial Protocol to Treat Prostate Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.comX
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com